Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Washington
Sunnybrook Health Sciences Centre
University of Ulm
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceutical K.K.
University College, London
Institute of Hematology & Blood Diseases Hospital, China
Kosin University Gospel Hospital
Shanghai Changzheng Hospital
University of Nebraska
Abramson Cancer Center at Penn Medicine
Hackensack Meridian Health
University College, London
University of Athens
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
University of Washington
University of Arizona
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Mayo Clinic
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Hoag Memorial Hospital Presbyterian
Hoag Memorial Hospital Presbyterian
National Cancer Institute (NCI)
SWOG Cancer Research Network
European Myeloma Network B.V.
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Northside Hospital, Inc.
National Cancer Institute (NCI)